Cargando…

Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod

BACKGROUND: Fingolimod efficiently reduces multiple sclerosis (MS) relapse by inhibiting lymphocyte egress from lymph nodes through down-modulation of sphingosine 1-phosphate (S1P) receptors. We aimed to clarify the alterations in peripheral blood T cell subsets associated with MS relapse on fingoli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Zi-Ye, Yamasaki, Ryo, Kawano, Yuji, Sato, Shinya, Masaki, Katsuhisa, Yoshimura, Satoshi, Matsuse, Dai, Murai, Hiroyuki, Matsushita, Takuya, Kira, Jun-ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412716/ https://www.ncbi.nlm.nih.gov/pubmed/25919001 http://dx.doi.org/10.1371/journal.pone.0124923

Ejemplares similares

Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis
por: Matsushita, Takuya, et al.
Publicado: (2013)

Genetic and Infectious Profiles Influence Cerebrospinal Fluid IgG Abnormality in Japanese Multiple Sclerosis Patients
por: Yoshimura, Satoshi, et al.
Publicado: (2014)

Genetic and Infectious Profiles of Japanese Multiple Sclerosis Patients
por: Yoshimura, Satoshi, et al.
Publicado: (2012)

Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod
por: Watanabe, Mitsuru, et al.
Publicado: (2020)

Connexin 43 Astrocytopathy Linked to Rapidly Progressive Multiple Sclerosis and Neuromyelitis Optica
por: Masaki, Katsuhisa, et al.
Publicado: (2013)

Association of Decreased Percentage of Vδ2(+)Vγ9(+) γδ T Cells With Disease Severity in Multiple Sclerosis
por: Maimaitijiang, Guzailiayi, et al.
Publicado: (2018)

Downregulation of Neuronal and Dendritic Connexin36-Made Electrical Synapses Without Glutamatergic Axon Terminals in Spinal Anterior Horn Cells From the Early Stage of Amyotrophic Lateral Sclerosis
por: Kobayakawa, Yuko, et al.
Publicado: (2018)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Extensive dysregulations of oligodendrocytic and astrocytic connexins are associated with disease progression in an amyotrophic lateral sclerosis mouse model
por: Cui, Yiwen, et al.
Publicado: (2014)

Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway
por: Li, Guangrui, et al.
Publicado: (2018)

Early and extensive alterations of glial connexins, distal oligodendrogliopathy type demyelination, and nodal/paranodal pathology are characteristic of multiple system atrophy
por: Nishimura, Yuji, et al.
Publicado: (2022)

Serum Anti-oligodendrocyte Autoantibodies in Patients With Multiple Sclerosis Detected by a Tissue-Based Immunofluorescence Assay
por: Miyachi, Yukino, et al.
Publicado: (2021)

Th1 cells downregulate connexin 43 gap junctions in astrocytes via microglial activation
por: Watanabe, Mitsuru, et al.
Publicado: (2016)

Connexin 30 Deficiency Ameliorates Disease Progression at the Early Phase in a Mouse Model of Amyotrophic Lateral Sclerosis by Suppressing Glial Inflammation
por: Hashimoto, Yu, et al.
Publicado: (2022)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
por: Yavari, Fatemeh, et al.
Publicado: (2021)

Latitude and HLA-DRB1*04:05 independently influence disease severity in Japanese multiple sclerosis: a cross-sectional study
por: Nakamura, Yuri, et al.
Publicado: (2016)

Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study
por: Saida, Takahiko, et al.
Publicado: (2017)

A new clustering method identifies multiple sclerosis‐specific T‐cell receptors
por: Hayashi, Fumie, et al.
Publicado: (2021)

Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis
por: Portaccio, Emilio
Publicado: (2011)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
por: Hunter, Samuel F., et al.
Publicado: (2015)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
por: Cohan, Stanley, et al.
Publicado: (2015)

Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis
por: Druart, Charlotte, et al.
Publicado: (2017)

Cardiac repolarization during fingolimod treatment in patients with relapsing–remitting multiple sclerosis
por: Laiho, Aapo, et al.
Publicado: (2018)

Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran
por: Ouspid, Elham, et al.
Publicado: (2018)

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Genetic factors for susceptibility to and manifestations of neuromyelitis optica
por: Matsushita, Takuya, et al.
Publicado: (2020)

Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension
por: Kira, Jun-ichi, et al.
Publicado: (2014)

Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy
por: Ogata, Hidenori, et al.
Publicado: (2015)

Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America
por: Correale, Jorge, et al.
Publicado: (2015)

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
por: Cohen, Jeffrey A., et al.
Publicado: (2019)

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
por: Derfuss, T, et al.
Publicado: (2020)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Contribution of cortical lesions to cognitive impairment in Japanese patients with multiple sclerosis
por: Shinoda, Koji, et al.
Publicado: (2020)

Iguratimod Ameliorates the Severity of Secondary Progressive Multiple Sclerosis in Model Mice by Directly Inhibiting IL-6 Production and Th17 Cell Migration via Mitigation of Glial Inflammation
por: Nagata, Satoshi, et al.
Publicado: (2023)

Long-term use of interferon-β in multiple sclerosis increases Vδ1(−)Vδ2(−)Vγ9(−) γδ T cells that are associated with a better outcome
por: Maimaitijiang, Guzailiayi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3jl99auteg10s9gj45473crklv